Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SH3GL interacting endocytic adaptor 1 (SGIP1) is a brain-expressed endocytic adaptor protein involved in clathrin-mediated endocytosis and energy homeostasis. SGIP1 interacts with multiple endocytic and scaffold proteins (including endophilins, Eps15, AP-2, intersectin), modulating plasma membrane curvature and vesicle formation through its membrane phospholipid-binding domain, proline-rich domain, and C-terminal μ-homology domain. The alternative splicing variant SGIP1α (in mice) is essential for clathrin-mediated endocytosis due to additional regions in its MP domain driving membrane deformation and oligomerization. SGIP1’s role in neuronal signaling, energy regulation, and potential involvement in metabolic and neuropsychiatric disorders—as well as its value as a biomarker for hepatocellular carcinoma—underscore its functional importance, though it is not currently a direct therapeutic target[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SH3GL interacting endocytic adaptor 1 (SGIP1).